Literature DB >> 25193460

Continuous infusion versus intermittent bolus dosing of morphine: a comparison of analgesia, tolerance, and subsequent voluntary morphine intake.

Gang Yu1, Fu-Qiang Zhang2, Shuai-En Tang2, Miao-Jun Lai2, Rui-Bin Su3, Ze-Hui Gong4.   

Abstract

Improved utilization of continuous or intermittent opioid administration in pain treatment necessitates a comparison of the antinociceptive effect and tolerance of these two treatment methods. More importantly, the effect of treatment method on subsequent opioid consumption has not been directly compared, although it is widely assumed that continuous opioid treatment may produce lower addictive liability relative to intermittent opioid treatment. In this study, we compared the antinociceptive effect and tolerance of morphine in rats that received repeated injection (10 mg/kg twice daily for 7 days) or continuous infusion (20 mg/kg daily for 7 days) subcutaneously and the self-administration of intravenous morphine in these rats after 7 days of withdrawal. Both intermittent and continuous morphine treatment produced antinociceptive tolerance, but the exhibition of tolerance differed. Moreover, intermittent morphine pretreatment facilitated subsequent morphine self-administration, whereas continuous morphine pretreatment produced minimal effects, as shown by comparable levels of active responses and morphine consumption between continuous morphine and saline-treated rats. These results suggest that the administration method of opioid should be selected according to the specific pain situation and that continuous opioid administration or long-acting therapy may be advantageous, producing less influence on drug-taking behavior than intermittent administration of short-acting drugs.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antinociception; Continuous infusion; Intermittent injection; Morphine; Self-administration

Mesh:

Substances:

Year:  2014        PMID: 25193460     DOI: 10.1016/j.jpsychires.2014.08.009

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  7 in total

1.  Clinical Interventional Oncology Symposium And Integrative Healthcare Symposium.

Authors:  Walter Alexander
Journal:  P T       Date:  2017-04

2.  Interruption of continuous opioid exposure exacerbates drug-evoked adaptations in the mesolimbic dopamine system.

Authors:  Emilia M Lefevre; Marc T Pisansky; Carlee Toddes; Federico Baruffaldi; Marco Pravetoni; Lin Tian; Thomas J Y Kono; Patrick E Rothwell
Journal:  Neuropsychopharmacology       Date:  2020-02-20       Impact factor: 7.853

3.  Deletion of the type 2 metabotropic glutamate receptor increases heroin abuse vulnerability in transgenic rats.

Authors:  Jun-Tao Gao; Chloe J Jordan; Guo-Hua Bi; Yi He; Hong-Ju Yang; Eliot L Gardner; Zheng-Xiong Xi
Journal:  Neuropsychopharmacology       Date:  2018-10-03       Impact factor: 7.853

4.  Intrathecal rapamycin attenuates morphine-induced analgesic tolerance and hyperalgesia in rats with neuropathic pain.

Authors:  Ji-Tian Xu; Linlin Sun; Brianna Marie Lutz; Alex Bekker; Yuan-Xiang Tao
Journal:  Transl Perioper Pain Med       Date:  2015

5.  Pharmacological modulation of neuropathic pain-related depression of behavior: effects of morphine, ketoprofen, bupropion and [INCREMENT]9-tetrahydrocannabinol on formalin-induced depression of intracranial self-stimulation in rats.

Authors:  Michael D Leitl; S Stevens Negus
Journal:  Behav Pharmacol       Date:  2016-06       Impact factor: 2.293

Review 6.  Reinforcement Learning for Clinical Decision Support in Critical Care: Comprehensive Review.

Authors:  Siqi Liu; Kay Choong See; Kee Yuan Ngiam; Leo Anthony Celi; Xingzhi Sun; Mengling Feng
Journal:  J Med Internet Res       Date:  2020-07-20       Impact factor: 5.428

7.  Novel intrathecal and subcutaneous catheter delivery systems in the mouse.

Authors:  Folabomi A Oladosu; Brittney P Ciszek; Sandra C O'Buckley; Andrea G Nackley
Journal:  J Neurosci Methods       Date:  2016-03-11       Impact factor: 2.390

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.